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Abstract 
Current therapies for adrenocortical carcinomas do not improv e 
the life expectancy of patients. I n this study, we tested whether a 
gene-transfer therapy based upon a suicide gene/prodrug system 
would b e effective in an animal mode l o f the disease. We em-
ployed E4- and ElA/B-depleted. herpes simplex virus-thymidine 
kinase-expressing adenovira l mutant s tha t transcomplemen t 
each other within tumor cells, hereby improving transgene de-
livery and efficacy by viral replication in situ. Transcomplemen-
tation o f vectors increase d th e fractio n o f transduced o f tumor 
cells. This increase was accompanied b y greater tumor volume 
reduction compare d t o non-transcomplementin g approaches . 
Survival tim e improve d wit h non-replicatin g vectors plu s GCV 
compared t o controls. However , transcomplementation/replica-
tion of vectors le d t o a furthe r significant incremen t in anti-tu -
mor activity and surviva l time (p <0.02). In treated animals, we 
observed a  hig h numbe r o f apoptoti c nucle i bot h adjacen t t o 
and distant from injection sites and sites of viral oncolysis. Ultra-
structural analyses exhibited nuclear inclusion bodies character-
istic o f virus production  i n situ,  an d provide d furthe r evidenc e 
that this therapy induced apoptotic cell death within tumor cells. 
We conclude that the efficacy of suicide gene therapy is signifi -
cantly amplified b y vira l replicatio n and , i n combinatio n wit h 
GCV, significantly reduces tumor burden and increases survival 
time. 
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Introduction 
Adrenocortical carcinoma s ar e sever e malignancies . Th e prog -
nosis is poor, as metastases in lung and liver develop rapidly; 5-
year survival rates range between 15 and 35% [1]. Two age peaks 
of higher incidenc e within th e 1 st an d 4 th decade s o f life hav e 
been reporte d [2,31 . Molecular , paracrine , immunologic , an d 
hormonal features of these tumors have been studied extensive-
ly, and prognostic signs have been developed [4]. Impaired cellu-
lar communication betwee n tumo r and effecto r cells of the im-
mune system may be related to immune surveillance due to the 
decreased MHC 3 clas s I I expressio n [5] . Interestingly , solubl e 
mediators of the immune system itsel f have been shown to pro-
mote adrenocortical tumors by the action of aberrantly express-
ed receptors [6]. However, despite efforts to shed light upon the 
molecular and immunologi c mechanism s leadin g t o neoplasti c 
degeneration in the adrenal gland, no effective treatments have 
been developed . Fe w chemotherapeuti c option s fo r patient s 
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bearing unresectabl e o r metastasizin g tumor s ar e available . 
Standard therapies have severe side effects, and evidence of their 
success is anecdotal [7-9]. 
Animal modelin g o f adrenocortical carcinom a wit h ne w treat -
ment modalitie s could accelerat e the developmen t of therapies 
for this disease, and may have broader application; however , no 
appropriate mode l i s currentl y available t o tes t possible treat -
ment strategies. CE mice have been reported to develop adreno-
cortical hyperplasi a wit h progressio n t o carcinom a afte r ovari -
ectomy [10]. This is highly suggestive of an involvement of regu-
latory hormones ; indeed , estradio l replacemen t prevente d de -
velopment o f transplanted carcinoma s i n mic e [11] . However , 
hormone-dependent adrena l carcinoma s hav e no t bee n de -
scribed i n humans with or without adrenal hyperplasia . To de-
velop a more pertinent animal mode l of this disease , we gener-
ated SW-13-derived human adrenocortical carcinoma xenografts 
in nude mice. The SW-13 cell line was initiated from an hormon-
ally inactive small-cel l carcinom a o f the huma n adrena l corte x 
[12] an d ha d previousl y bee n use d t o tes t compound s wit h 
some chemotherapeutic capacity [13- 15]. 
Gene-transfer therapy could improv e treatmen t of adrenocorti-
cal carcinomas . A principa l limitatio n of gene therapy i s ineffi -
cient gen e deliver y [16] . Therefore , biologica l amplificatio n o f 
anti-tumor effects agains t both transduce d an d non-transduce d 
tumor cells has been sought in the recruitment of host immune 
effector cells [17] , production of antiangiogenic factors [18-21] , 
or the use of suicide genes. The prototypical suicide gene, herpes 
simplex virus (hsv)-thymidine kinase (TK), activates a relatively 
non-toxic prodrug (such as Ganciclovir) to a cytotoxic compound 
[22,23]. In addition to direct toxicity in the transduced cell, the 
expression of hsv-TK causes cell death in non-transduced tumor 
cells via  a "bystander effect," which transfers the activated pro-
drug fro m hsv-T K expressin g cell s t o adjacent , metabolicall y 
coupled cells [24-27]. 
Anti-tumor strategies have recently been modified b y including 
viral replication as a means of increasing intratumoral transgene 
delivery [28 ] an d a s a n inductio n o f direc t vira l cytotoxicit y 
[29,30]. In anima l model s using adenoviruses with attenuated 
replication potential , increase d surviva l ha s bee n demonstrated 
[31 ]; a further improvement was reported when partial replica-
tion competenc e wa s combine d wit h suicid e gen e expressio n 
[30]. However , adenovira l vector s expressin g herpes  simplex 
virus-thymidine kinas e ma y damag e proliferatin g non-cancer -
ous tissues, and can cause severe liver necrosis, including death 
in animal models after systemic application [32,33]. Such toxici-
ties may be even mor e prominen t i n systems usin g replication 
competent vectors expressing hsv-TK. 
As a  ne w therapeuti c approac h fo r adrenocortica l cancer , w e 
modified the replicating vector strategy to utilize replication-de-
pendent vector distribution within th e tumor, bu t sought to re -
duce systemic vector spread, potentially minimizing side effects. 
To achieve this, we employed two replication-deficient adenovi-
ral vectors, E4-deleted \\5.dll014 [34] and an ElA/B-deieted vec-
tor carrying a herpes simplex vin/s-thymidine kinase gene cloned 
into a vector derived from H5.d/309 (AVC2.TK). The two separate 
adenoviral variant s ar e individuall y replication-deficien t du e t o 
defects i n essentia l vira l genes (in cis-)  bu t replication-compe-
tent whe n combine d i n cell s via  transcomplementation . Thi s 
system was tested to establish whether replication results in in-
creased vecto r spread withi n tumor s followin g co-transduction 
and whether anti-tumor efficacy i n adrenocortical tumo r xeno-
grafts i s improve d b y thi s approach . The i n vivo  tumor mode l 
was characterized by radiographic and histological studies. Ade-
noviral vectors have been injected into xenograft tumors directly 
to achieve efficient transduction of tumor cells b y both vectors. 
We the n use d FAC S analysis , immunohistochemistry , i n situ 
end-labeling, ultrastructura l analyse s t o monito r gene transfer , 
virus particl e production, apoptotic cell death , and virus/trans -
gene-mediated tumor lysis. Our findings show that co-transduc-
tion o f adrenocortical tumo r cell s enable s transcomplementa -
tion and result s i n replicatio n o f vectors. This loca l productio n 
of vector leads to a further increase in the fraction of transduced 
tumor cells and enhances transgene distribution, hereby improv-
ing efficacy of suicide gene/prodrug strategy. 
Materials and Methods 
Cells 
293 cells»(CRL-1573). Yl cells (CCL-79), AtT20 ceils (CCL-89), and 
SW-13 cells (CCL-105) (12) were obtained from ATCC (Gaithers-
burg, MD). WI62 cells were kindly provided by G. Ketner (Johns 
Hopkins U., Baltimore, MD). Rat 9L cells were kindly provided by 
E. Oldfield (N1NDS, Bethesda, MD). All cell lines were grown in 
DMEM medium supplemented with 10% FCS, 2 mM L-glutamine, 
lOOU/ml penicilli n and lOOug/m l streptomyci n (Life Technolo-
gies, Grand Island, NY) at 37 C in 10% C02. 
Adenoviral vectors 
AVC2.null i s identica l t o AVC2.TK except fo r the absence of the 
hsv-TK transgene , and wa s generated b y the techniqu e o f Gra-
ham [35] . Briefly , th e adenovira l shuttl e plasmi d pAVC 2 [36 ] 
was introduce d int o pJM17 [37 ] b y Ca-phosphate co-precipita -
tion techniqu e i n 29 3 cell s [35] . Recombinan t El-delete d 
AVC2.TK was generated by the technique of Okada [38]. Hsv-TK 
function was confirmed by transduction of rat 9L cells at a multi-
plicity of infection (MOI) of 50 PFU/cell, exposure to ganciclovir, 
and measuremen t o f 3H-thymidine incorporation . AV.G L i s a n 
El-deleted virus expressing green fluorescent protein unde r the 
control o f the EFl- a promoter (kindly provide d b y J. Wahlfors , 
University o f Kuopio, Finland) . Th e E 4 mutan t dll014  (kindl y 
provided by G. Ketner, Johns Hopkins University) was grown on 
WI62 cell s an d isolate d b y standar d technique . Viruse s wer e 
plaque-purified twice , amplifie d usin g th e standar d technique , 
and analyze d b y restrictio n digestio n o f proteinas e K-digeste d 
viral DNA. All viral stocks were plaque-titered in triplicate by se-
rial dilutio n an d aga r overlay on thei r respectiv e transcomple-
menting cell lines according to standard protocols. 
In vitro transduction and FACS analyses 
For in vitro transduction, SW-13 ceils, AtT20- and Yl-cells were 
plated in 6-well plates at a density of 300 000 ceils per well. Cells 
were transduced with MOls of 1 to 100 PFU/cell. After 80 h. cells 
were trypsinized , harveste d b y centrifugation and resuspende d 
in ice-cold HBSS containing 5% FCS and 0.1 M EDTA (Sigma, St. 
Louis, MO). Cells were subjected to FACS analysis using a Becton 
Dickinson FACSort analyzer and 1000 0 ungated events were col-
lected for analysis. 
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Mice and tumor generation, treatment groups 
6-8 week-old femal e nud e mice were obtained fro m DCT (Fre-
derick, MD) . Mic e wer e injecte d subcutaneousl y int o th e righ t 
flank with 10 x 106 cells in 200pi HBSS (Biofluids, Gaithersburg, 
MD) containin g 20 % Matrige l (Collaborativ e Biomedica l Pro -
ducts, Waltham, MA). Weekly monitoring of tumor size was car-
ried out by measurement diameters in three dimensions at right 
angles with calipers [volume = 1 x wxh]. In vivo transduction was 
performed whe n tumor s gre w t o a  mea n volum e o f 300 mm3. 
Treated tumors were injected with 2 * 109 PFU of adenoviral vec-
tor in a volume of 100 pi using 25 g needles. In treatment groups, 
GCV (Roche Bioscience, Palo Alto, CA) was injected intraperitone-
ally twice daily for 5 days at a dose of lOOmg/kg/d. Animals were 
injected with 1  x io9 PFU AVC2.TK plus 1  x lo9 PFU AV.d//0J4, 
groups [TK/d/I0J4/GCV 80] ( n = 8) an d [TK/d/70J4/GCV 30] ( n = 7) 
or 2 x 109 PFU AVC2.TK, group [TK/GCV) (n = 9) to compare trans-
complementing vs . replication-defectiv e vecto r approache s o f 
therapy. Ganciclovi r was injecte d intraperitoneall y after 80h i n 
group [TK/dl/0/4/GCV 80| an d additionall y afte r 30 h i n grou p 
[TK/d//0/4/GCV30] to compare early and late blocking of viral re-
plication. Two control groups [TK/dUOM] (n = 9) and [TK] (n = 8) 
were transduced as groups [TK/d/?0/4/GCV80] and [TK/GCV], but 
did not receive GCV. \dll014] (n = 9) was transduced with 2 x io9 
PFU AV.d/1014 alone, [GCV] (n = 9) was only treated with GCV and 
(untreated) (n = 9) received n o treatment. Animals were eutha-
nized when tumor size exceeded 150 0 mm3. All anima l experi -
ments wer e conducte d i n accordanc e wit h NI H guideline s fo r 
the care and treatment of laboratory animals. 
Planar imaging/positron emission tomography 
The accumulation o f F-18 fluorodeoxyglucos e (FDG) in th e im-
planted adrena l tumor s wa s imaged tomographically in severa l 
mice by planar imaging/positron emission tomograph (PiPET), a 
device develope d specificall y fo r imagin g smal l animals . FD G 
was administere d b y tai l vei n injectio n (15 0 microcuries / 
0.1 ml). At 30 minutes post-injection, the animal was fixed to a 
vertical rotation device between the two PiPET detectors and ro-
tated continuousl y fo r 30min during acquisition o f all possibl e 
coincidence lines connecting the two detectors. Two sequential 
data collections were performe d wit h th e firs t collection bein g 
used t o visualize the subcosta l region s of the animals followe d 
by a second, which visualized the more rostral areas of the ani-
mals. Thes e tw o dat a set s wer e reconstructe d wit h filtere d 
back-projection (ram p filter ) and , afte r variou s corrections , 
merged to form a continuous tomographic representation of the 
distribution of FDG in the whole animal. 
Electron microscopy 
Small tissue pieces of adrenal tumor were fixed in 4% paraform-
aldehyde - 1 % glutaraldehyde in 0.1 mol/1 phosphate buffer, pH 
7.3, for 3 h, postfixed in 2% Os04 in 0.1 mol/1 cacodylate, pH 7.3, 
dehydrated in ethanol, and embedded in epoxy resin. 70 nm sec-
tions were stained wit h urany l acetate and lea d citrate and ex -
amined at 80 kV under a Phillips electron microscope 301 (Phil -
lips. Rahway, NJ). 
In situ labeling of DNA fragments 
The staining of apoptotic nuclei was achieved by non-radioactive 
in situ  end-labeling . The free 3'-ends o f cellular DNA served as 
template an d Wer e elongate d an d labele d wit h digoxigenin -
marked deoxyUTP. The digoxigenin was subsequently immuno-
detected with anti-DI G peroxidase , visualized wit h 3-amino-9 -
ethylcarbazole (AEC) and counterstained with methylene green. 
In additiona l experiments , immunodetectio n an d visualizatio n 
were carried out with anti-digoxigenin-rhodamine conjugate ac-
cording to the suppliers protoco l (ApopTag®-Kit , Intergen Com-
pany, Purchase, NY). 
Statistical analyses 
All in vitro experiments were performed in quadruplicate. Statis-
tical analyse s wer e performe d wit h Prism2/GraphPa d softwar e 
using the Mann-Whitney test for evaluation of tumor volume ex-
periments and the Kaplan-Meier method for survival curves. Re-
sults were considered statistically significant where p < 0.05. 
Fig. 1 Vecto r maps of AVC2.TK and 
AV.dl1014. AVC2.TK has a deletion in early 
region 1 , in which the CMV promotor and 
herpes simplex type I thymidine kinase have 
been inserted. AV.dll014 has a deletion in 
early region 4 with only open reading frame 
4 left (F.4orf4). Both deletions render the 
adenoviral vectors replication incompetent, 
however, if El an d E4 products will be 
expressed in a single cell from both vectors, 
replication can occur due to transcomple-
mentation. Horizontal black bars in the fig-
ure depict early region 1  or  4 by which gene 
products have to be supplemented to the 
second vector. 
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Fig. 3 Transductio n of tumor cells in vitro. Cells plated in 6-well plates 
at a density of 3 * 10"J cells per well were transduced with AV.CL at MOI 
of 1 t o 100 PFU/cell, harvested after 80 h and subjected to FACS analy-
sis. Maximu m transductio n fo r huma n adrenocortica l SW-1 3 an d 
mouse pituitar y AtT20-cell s wa s achieved a t MOI s o f 30PfU/cell . A t 
higher MOIs no further increase in transduction rate could be detected 
and virus dependent cytotoxity increased (data no t shown). 
Fig. 4 I n vivo transduction of human adreno-
cortical cell xenografts. A Tumor s were trans-
duced in vivo  with eithe r 2  * 109 PF U AVC2. -
null, 1 x 10'1 PFU AV.GLp/us 1 x 109 PFU AVC2.-
null o r 1*10 9 PF U AV.C L plus  1x10 ° PF U 
H5.d!10l4 and transgen e expression wa s as -
sessed by FACS analyses. Tumors transduced 
with transcomplementin g vector s exhibite d 
an u p t o 4-fol d highe r rat e o f transduction , 
median transductio n efficienc y wa s 9.8 % 
with non-transcornplementin g viruse s an d 
36.7% fo r transcomplementin g transduce d 
tumors (p<0,05) . B  Transmissio n electro n 
micrographs demonstrating nuclear.vira l par -
ticles in situ. Transcomplementing transduced 
tumors wer e examined fo r newl y assembled 
viral particle s 9 6 h afte r transduction . D e 
novo assemblin g o f vira l particle s insid e th e 
nucleus is a characteristic feature of virus pro-
duction and indicative for replication. The fig-
ure depicts characteristi c adenoviral particles 
with circula r electro n dens e structur e an d 
halo as nuclea r inclusions in a  SW-1 3 tumor 
cell. 
Fig. 2 Huma n adre-
nocortical xenograft 
tumors in nude mice, 
A Femal e nude mice 
were injected subcu-
taneously into the 
right flank wit h 




neously and afte r 6-
7 weeks metastases 
occurred. B Whole -
body volume repro-
jection image of an 
adrenal tumor-bear-
ing mouse after injec-
tion of 18F-FDG. Pri-
mary tumor (T) and 
metastasis (M)ar e 
visible. Two data 
collections were 
required to visualize 
the whole animal 
(H = heart, BR = brain, 
HA = Harderian 
glands, B = bladder). 
Results 
Characterization o f tumor model 
SW-13-derived tumor nodules were established in the flanks of 
nude mic e b y subcutaneou s and/o r intraderma l injectio n o f 
10 * 106 cells. The adrenocortical tumor model used in this study 
was a progressive and lethal disease with no evidence of sponta-
neous regression . Animal s wit h ulceratin g tumor s o r tumor s 
greater than 150 0 mm3 wer e euthanized, and are referred t o in 
the assessment of the survival rate as "succumbed to tumor bur-
den". Tumors reached an average volume of 300 mm3 by 5 weeks 
after inoculation. By 7 to 9 weeks, metastases could be detected 
by visual examinatio n (Fig.2 A) or gross dissection an d metas -
tatic tumor deposits could be readily localized by PET scan with 
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18F-FDG (Fig.2B) . Histologica l studie s reveale d multilobulate d 
tumors wit h an adrena l glandula r textur e (Fig . 6). They devel -
oped a  pseudo-capsule and were highly vascularized. Histolog y 
of th e primar y an d metatstati c tumo r deposit s demonstrate d 
characteristic signs of their common origin; bot h demonstrated 
compact cells with pleomorphic nuclei and an abundance of mi-
In vitro transduction with AV.GL 
SW-13 cells were transduced in vitro with AV.GL at MOls of 1 to 
30PFU/cell. Transductio n efficienc y wa s compare d t o mous e 
adrenocortical Yl cell s and the pituitary cell line AET20. A high 
rate of transduction i n human SW-13 cells occurred a t MOls of 
10 to 30 PFU/cell, whereas murine cell lines showed a vastly low-
er transduction rate (Fig.3). At MOls of 100PFU/cell. no further 
increase i n transductio n rat e coul d b e detected , an d virus-de -
pendent cytotoxicity increased . 
totic figures. Tumor cell masses could frequently be found on the 
outer side of the pseudo-capsule and occasionally within pene-
trating vessels. On the ultrastructural level, tumors exhibited mi-
tochondria with tubulovesicular structure and ample smooth en-
doplasmic reticulu m typica l o f adrenocortical cells . The tumo r 
cells di d no t expres s ga p junctions b y ultrastructura l analysi s 
(see Figs. 4B and 7) or immunohistochemistry (data not shown). 
Fig. 5 Treatmen t o f huma n adrenocortica l SW-1 3 xenograf t tumors 
in nud e mice . Tumor s wit h a  mea n volum e o f 3.0 0 mm3 (vol -
ume = I x w x h) were transduced with 2 * 109 PFU of either trans-com-
plementing o r non-replicatin g adenovira l vectors . Ganciclovi r 
("IQOmg/kg/d) was given in divided doses twice daily for 5 days by in-
traperitoneal injection . Contro l animal s receive d eithe r vira l vecto r 
without GCV or GCV alone. A Th e additive effects of TK, transcomple-
mentation an d GC V administration markedl y improved surviva l com-
pared to [TK/GCV] (p<0.02). Median survival time was 50 d (p = 0.07) 
forfJK/GCV], and 60.5 d (p.= 0.002) for animals transduced with trans-
complementing vectors but without ganciclovir (transcomp). B Tumo r 
size was monitore d weekly . Growt h inhibitio n an d tumo r volum e re-
duction in animal s receiving transcompiementating vectors plu s GCV 
at 80h[transc/GCV/80] post-transductio n was superior to all other ap-
proaches, including non-replicating AVC2.TK plus GCV treatment (after 
29 d; p » 0.001). Transcomplementin g transduction wit h vira l replica -
tion retarded by administration of GCV at 30 h post-transduction dem-
onstrated a  noticeable , bu t statisticall y insignifican t improvemen t 
comparable to AVC2.TK pZusH5.dll 014 without GCV. 
Fig. 6 Fre e 3'-end s o f DN A of apoptotic nucle i wer e labeled wit h di -
goxigenin-marked deoxyUTp , subsequentl y immunodetecte d wit h
anti-DIG-peroxidase and visualized with AEC. Fig.6 A shows an AV.GL
transduced SW-13 tumor with single apoptotic nucle i and cell clusters 
•with brown stained nuclei throughout the specimen. I n Fig. 6B apop-
totic foc i wer e frequentl y foun d adjacen t t o site s o f injection an d t o 
areas withi n th e tumo r demonstratin g vira l transductio n a s demon -
strated by flourescence induction of the transgene (bar = 50 Lim). 
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Fig.7 Ultrastructural analysis of cell death in 
tumors Xenografts transduced with trans-
complementing adenoviral vectors AVC2.TI< 
plus H5.dI1074. Tumors exhibited mitochon-
dria with tubulo-cristular structure typical of 
adrenocortical cells. A Cells showed apopto-
tic signs such as vacuolization of the nucleus 
(N) and cytoplasm, but only a slight conden-
sation of chromatin and fragmentation of nu-
clei. The mitochondria (M) exhibited in this 
figure remained morphologically unaffected, 
indicating a grossly intact metabolism in 
these cells (bar ~ 1 Ilm). B Higher magnifica-
tion of the inset from Fig. 7 A demonstrating 
intranuclear viral particles (arrows) indicative 
of viral replication (bar ~ 0.1 Ilm). . 
In vivo transduction and transcomplementation 
Tumors (n ~ 10) were transduced in vivo with either 2 x 109 PFU 
AVC2.null, 1 x 109 PFU AV.CL plus 1 x 109 PFU AVC2.null, or 
1 x 109 PFU AV.CL plus 1 x 109 PFU AV.dI1014. Tumors were har-
vested, digested with triple enzyme solution [39], and transgene 
expression was assessed by FACS analyses 72 and 96 h after in-
jection. Tumors transduced with transcomplementing vectors 
exhibited up to 4 times the rates of transduction. Median trans-
duction efficiency was 9.8 % with non-transcomplementing viru-
ses and 36.7 % for tumors transduced with vectors that trans-
complement (p<0.05; Fig.4A). The percentage of transduced 
cells remained constant after three days, suggesting that a steady 
state between viral de novo transduction and cell loss via viral 
cell lysis is reached in this time frame. 
Treatment of adrenocortical cell tumors 
Tumors with an average volume of 300 mm3 at the time of treat-
ment were injected with 2 x 109 PFU of adenoviral vector. The ef-
fect of the treatment was monitored by weekly measurements of 
tumor size and assessment of survival. 
A suppression in the growth of SW-13 derived tumors could be 
observed in all animals transduced with vectors expressing hsv-
TK and treated with CCV (groups [TK/dI1014/CCVao ]. [TK/dI1014/ 
CCV30 ] and [TK/CCV]) within 15 days after onset of treatment. 
Shrinkage of the tumors in group [TK/dI1014/CCVao ] continued 
up to 30 days after CCV treatment (Fig. S A). Interestingly, there 
was a gradation of effectiveness in growth inhibition and volume 
shrinkage. The gradation was dependent on time allowed for 
completion of virus replication and ganciclovir administration; 
growth inhibition after transcomplementing transduction with 
CCV treatment 80 h post-transduction was superior to trans-
complementing transduction and CCV treatment 30 h post-
transduction as well as tumors transduced with AVC2.TK plus 
CCV treatment and significant after 29 d (p = 0.001; Fig. SA). 
The tumors grew continuously in the untransduced control 
groups [CCV] and [untreated] and in the AVC2.TK and AV.d/1014 
transduced control groups [TK] and [dI1014]. 
Survival was poor in the control groups with an average survival 
rate below 37 % after 4 weeks and below 25 % after 6 weeks, with 
a median survival time of 29 d. Median survival in single groups 
was: [CCV] = 22 d, [untreated] = 22 d, and [dI1014] = 29 d. In con-
trast, mice with transduced tumors and CCV treatment had a no-
tably prolonged survival when compared to controls. The medi-
an survival time was 50 d (p = 0.07) for AVC2.TK with CCV treat-
ment (group [TK/CCV]), and 60.5 d (p = 0.002) for animals trans-
duced with transcomplementing vectors but without CCV 
(group [TK/dI1014]). Importantly, administration of CCV to trans-
complementing transduced animals further improved survival 
significantly (Fig. S B, P < 0.02), showing additive effects of TK. 
transcomplementing and CCV administration. There was no sta-
tistical difference between transcomplementing transduced ani-
mals with early (after 30 h) or delayed (after 80 h) administration 
of CCV, groups [TK/dI1014/CCV30 ] and [TK/dI1014/CCVao ]. The 
survival was 100% in the transcomplementing transduced group 
with CCV treatment 80 h after transduction after 6 weeks and 
declined minimally to 85 % at the termination of the experi-
ments, providing an estimated median survival time of 1.2 years 
by regression analyses. 
Analyses of cell death in adrenocortical-small 
cell carcinoma after transduction 
Tumors were examined 96 hours after transduction to explore 
the mechanism oftumor-cell death induced by this therapy. The 
cleavage of nuclear DNA with a characteristic pattern of frag-
mentation is a hallmark of programmed cell death. The free 3'-
ends ofthese fragments are available for labeling and thus allow 
detection of apoptotic nuclei within a tissue specimen. In trans-
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duced SW-13 tumors, we observed single apoptotic nuclei as 
well as groups and cell clusters with stained nuclei throughout 
the specimens (Fig. 6A). Clusters were frequently found adjacent 
to sites of injection and virus replication (Fig. 6B). 
To further examine this prominence of apoptosis, we investigated 
transduced and non-transduced tumors by electron microscopy. 
Ultrastructural analyses showed signs of apoptosis such as con-
densation of chromatin and cytoplasm, but also vacuolization of 
the nucleus and cytoplasm. Cytosolic organelles such as mito-
chondria remained morphologically unaffected, indicating a 
grossly intact metabolism in these cells. Most often, slight con-
densation of chromatin and fragmentation of nuclei with blebbing 
and a vacuolated structure were observed, especially when the 
nucleus contained inclusion bodies as a sign of viral replication in 
the transcomplementing transduced groups (Figs. 7 A and B). 
Discussion 
In this study, we tested virally-mediated suicide gene therapy in 
a human xenograft model of adrenocortical carcinoma in nude 
mice. Transfer of the suicide gene hsv-TK with in situ transcom-
plementation of vectors and the subsequent administration of 
the antiviral drug GCV was a powerful tool against SW-13 de-
rived adrenocortical tumors. The anti-tumor effects of viral cy-
tolysis and transgene-mediated tumor cell ablation yielded 
more effective inhibition of tumor growth and significantly in-
creased the survival rate in this model. 
In the presented study, we used two separate viral species with 
either E4 (H5.dI1014) or E1A/B deletions (AVC2.TK; Fig. 1 ) that 
are replication deficient in cis- but replication-competent in co-
transduced cells. Transcomplementation in one cell creates a 
permissive environment for amplification and local spread of 
both vectors. The selection of H5.d11014 to transcomplement El 
defects of AVC2.TK was based on its unique properties related to 
the solely expression of E4orf4 of the E4 gene products. The 
E4orf4 protein itself is cytotoxic when expressed in multiple 
transformed cell lines [40]. Induction of a p53-independent 
pathway is implicated in the apoptotic death caused by E40rf4 
expression in the cell lines that were tested [41]. The ability of 
dl1014 to kill transduced tumor cells beyond the focus of trans-
complementation enabled replication may greatly increase its 
utility as the vector that supplies the El-transcomplementing 
function. Although we have not seen statistically significant 
anti-tumor activity of dl1014 when used as a monovalent vector, 
no amplification or spread of the virus is possible in the absence 
of E4-transcomplementation, and toxicity induced in 5 -10% of 
the cells within injected tumors is undetectable by measuring 
tumor volumes. However, in situ end-labeling of nuclei reveals 
increased intratumoral apoptosis at sites both adjacent and dis-
tant to areas of viral replication following tumor transduction 
(Fig. 6). Transgene expression, direct viral cytotoxity or stimula-
tion of normal apoptotic pathways that appear to be otherwise 
diminished might have contributed to this phenomenon [49]. 
In our model, tumor lysis by transcomplementation alone in-
creases survival time to 60 days, consistent with recent reports 
on beneficial oncolytic effects through replicating adenoviral 
vectors without suicide gene [42]. The expression of both El 
and E4 gene products are essential for viral replication; there 
are wide areas of tumor tissue subjected to cell lysis when the 
transcomplementing approach is used (Fig. 6). In addition, ultra-
structural analyses demonstrate nuclei with many inclusion 
bodies and altered morphologies in treated tissues, evidence of 
viral replication and associated cytopathic effects. 
Viral replication in the transcomplementing system improves 
transgene distribution. Ninety-six hours after vector injection, 
there is a cell transduction rate 4 times above that seen in trans-
ductions using non-transcomplementing vectors. In this way, su-
perior transgene spread relative to replication-deficient vectors 
in vivo was achieved as visualized through AV.GL-expression 
(Fig. 4). The efficacy of the hsv-TK transgene and/or E40rf4 in-
creased in a manner dependent upon viral replication in our sys-
tem and, therefore, significantly improves estimated median sur-
vival in an additive manner when combined with GCV. Replica-
tion-attenuated adenoviral vectors have been tested in systemic 
and local application strategies for biological amplification of 
anti-tumor effects [30,43], and additive benefits after GCV treat-
ment have been reported [44]. It is noteworthy, however, that re-
plication-attenuated vectors with El B deletions may require 
dysfunctional p53 mechanisms for viral replication to occur 
[29]. As such, this approach may not be suitable for treatment of 
approximately two-thirds of adrenocortical carcinomas, which 
possess intact p53. 
Gap junctions enable distribution (local bystander effect) of toxic 
GCV metabolites into neighboring cells, leading to wider cell ab-
lation, but many human malignancies form few if any gap junc-
tions [45,46]. In fact, the original tumor from which SW-13 was 
derived was reported not to express gap junctions; in our ultra-
structural and immunohistochemical analyses, gap junctions 
could not be observed. This is consistent with recent reports on 
decreased numbers of intercellular junctions in adrenocortical 
tumors in vivo [47]. Although gap-junction expression can be im-
proved through several compounds [48], a substantial benefit 
may be achieved by the spread of the suicide gene(s) rather 
than toxic metabolites, using our transcomplementing system 
in tumors lacking significant gap junctions. Further on, healthy 
untransformed cells are more likely to become affected by the 
bystander effect since they adequately express gap junctions. 
However, there is no information available concerning an inad-
vertent bystander effect in healthy cells, and the impact of this 
probably toxic side effect has yet to be determined. 
In our nude mouse model, efficacy is dependent upon the addi-
tive effects of direct viral cytotoxity and TK/GCV induced cell 
death in a fashion independent of normal immune effectors. 
Nevertheless, tumor lysis induced by specific gene transfer 
therapies has been suggested for improving the host's immune 
response in some models [17] and allows speculation of further 
increments in efficacy in immunocompetent organisms. Inter-
estingly, communication between T-Iymphocytes and adreno-
cortical cells has been reported [50]. Normal adrenocortical cells 
express MHC class 11 molecules, but this is diminished in adreno-
cortical tumors [5], and this disruption may be implicated in the 
escape of adrenocortical tumors from immune surveillance. In-
deed, we have found that upregulation of MHC class I molecules 
occurs during apoptosis in rat glioma cells expressing hsv-TK 
after GCV administration and that this is associated with im-
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proved anti-tumor responses which can retard progression of, or 
ablate, distant tumor deposits (W.].R., personal observation). Up-
regulation of MHC molecule expression induced by the therapy 
we describe may then improve host anti-tumor immunity in 
models where intact immune functions are present. Virus-medi-
ated cell lysis will cause a release of mediators, which then acti-
vates the immune system and surrounding infected cells and -
eventually - the viral cycle as well. 
Inadvertent dissemination or systemic application of vectors ex-
pressing hsv-TK and even inactivated virus particles lacking 
transgene expression may cause severe liver damage, inflamma-
tion and necrosis, and death in experimental animals after expo-
sure to GCV has been reported [32,33]. Similarly, liver toxicity 
through non-replicating vector administration has been seen in 
primates and humans [51]. However, in the model investigated, 
release of virus from transduced tumors is accompanied by a di-
lutional effect that stochastically diminishes the likelihood of 
generating the co-transduced conditions necessary for viral rep-
lication. Furthermore, H5.d11014 expresses only the orf4 peptide 
of early region 4 and, therefore, cells infected in vitro with 
H5.d11014 demonstrate only minimal viral DNA replication, 
which is unique among E4 mutants [34,52]. When cells are in-
fected in the absence of E40rf6 or E4orf3, E4orf4 downregulates 
the activity of E1A proteins. This leads to reduced expression of 
viral genes dependent upon E1A R289 phosphorylation and 
causing the observed replication deficient phenotype [53 - 55]. 
Separate studies will be necessary to establish what dose-limit-
ing toxicities exist in this model and if modifications can lessen 
any such toxicity. In addition, a restricted opportunity for the 
generation and release of pseudo-wild type revertants must be 
carefully considered and addressed when the transcomplement-
ing approach should be used in a clinical setting. However, the 
chance of recombination-mediated reversion to wild type ade-
novirus is low [56]. 
In summary, our findings demonstrate that this novel transcom-
plementing system of adenoviral vectors significantly enhances 
hsv-TK/GCV suicide gene therapy for cancer. Blockade of tumor 
growth improves and survival time is greatly prolonged. The 
mechanisms underlying tumor growth retardation and/or abla-
tion involve increased replication-dependent cytoloysis and 
more efficient transgene delivery, which provide improved local 
bystander effects and are characterized by a high frequency of 
apoptotic cell death in transcomplementing transduced tumors. 
Transcomplementing vectors are a promising system, displaying 
enhanced local transduction rates but low systemic toxicity. 
When used as vehicle for delivery of the hsv-TK transgene, signif-
icant therapeutic benefits can be observed in a model of adreno-
cortical cancer. This approach may be refined to become a new 
treatment option for patients with advanced adrenal cancer. 
Abbreviations 
GCV: Ganciclovir; hsv-TK: herpes simplex virus type one thymi-
dine kinase; MOl: multiplicities of infection; MHC: major histo-
compatibility complex. 
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